Demaria Sandra, Coleman C Norman, Formenti Silvia C
Department of Radiation Oncology, Weill Cornell Medicine, 1300 York Ave, Box 169, New York, NY 10065.
Radiation Oncology Branch, Center for Cancer Research and Radiation Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, MD.
Trends Cancer. 2016 Jun;2(6):286-294. doi: 10.1016/j.trecan.2016.05.002.
Immune checkpoint inhibitors are effective in cancer treatment. A pre-existing immune response demonstrated by significant pretreatment tumor lymphocytic infiltration is a pre-requisite for response. Within such infiltrated tumors, referred as "hot", immune checkpoint inhibitors rescue anti-tumor T cells activity. In contrast, "cold" tumors lack lymphocytic infiltration and are refractory to immunotherapy. Preclinical data show that radiotherapy sensitizes refractory tumors to immune checkpoint inhibitors by recruiting anti-tumor T cells. Despite the growing number of clinical studies testing radiation's ability to enhance immunotherapy, clinical evidence that it converts cold tumors into responsive ones remains elusive. Here we review evidence that radiotherapy is not only an occasional enhancer of immunotherapy's effects but a "game changer", and propose a blueprint to test this.
免疫检查点抑制剂在癌症治疗中有效。显著的预处理肿瘤淋巴细胞浸润所证明的预先存在的免疫反应是产生反应的先决条件。在这种被称为“热”的浸润性肿瘤中,免疫检查点抑制剂可恢复抗肿瘤T细胞的活性。相比之下,“冷”肿瘤缺乏淋巴细胞浸润,对免疫疗法难治。临床前数据表明,放疗通过募集抗肿瘤T细胞使难治性肿瘤对免疫检查点抑制剂敏感。尽管越来越多的临床研究测试了放疗增强免疫疗法的能力,但放疗将冷肿瘤转化为反应性肿瘤的临床证据仍然难以捉摸。在此,我们综述了放疗不仅是免疫疗法效果的偶尔增强剂,而且是“改变游戏规则者”的证据,并提出了对此进行测试的蓝图。